<DOC>
	<DOCNO>NCT00000942</DOCNO>
	<brief_summary>The purpose study see give anti-HIV drug nevirapine ( NVP ) HIV-positive pregnant woman baby help reduce chance mother give HIV baby delivery . Previous study suggest NVP promising medication block HIV transmission HIV-positive mother baby .</brief_summary>
	<brief_title>A Study Nevirapine Prevent HIV Transmission From Mothers Their Babies</brief_title>
	<detailed_description>NVP several property make attractive candidate antiretroviral therapy interrupt HIV-1 transmission intrapartum early post-partum period . The pharmacokinetic profile suggest NVP would rapidly absorb transferred infant utero give labor delivery . The HIV-1 antiviral activity rapid significant reduction plasma virus occur within day drug administration . In addition , NVP show penetrate cell-free virion inactivate virion-associated RT situ . This property would potentially useful inactivate cell-free virion genital tract well breast milk . These characteristic NVP suggest treatment HIV-infected pregnant woman labor oral dose NVP may provide prophylactic level NVP infant time exposure virus birth canal and/or maternal blood . In addition , NVP may inactivate virion-associated RT present cell-free virion genital tract breast milk . Mothers randomize receive either single oral dose NVP labor correspond NVP placebo . Randomization occur time 28th week gestation . To assure balance treatment group , randomization stratify use 2 factor : 1 ) use antiretroviral therapy current pregnancy ( antiretroviral therapy ; monotherapy [ multi-agent therapy ] duration ; multi-agent therapy duration ) , 2 ) CD4 cell count time randomization ( le 200 cell ; 200 399 cell ; 400 cell great ) . Mothers follow on-study 4 6 week postpartum . Due result ACTG 076 185 , woman entry ACTG 316 encourage incorporate regimen zidovudine ( ZDV ) current treatment regimen continue ZDV delivery neonate ( least 6 week post-birth ) . Infants receive single oral dose NVP ( correspond placebo ) administer 48 72 hour life . The infant 's study drug mother 's randomize treatment assignment . Infants dose study drug accord randomization group regardless whether mother receive study drug . Infants follow 6 month life , test HIV birth , 4 6 week life , 3 month life , 6 month life .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive pregnant woman . Have pregnant least 28 week . Are least 13 year age ( consent parent guardian require 18 ) . Exclusion Criteria You eligible study : Your baby live . You intend breastfeed . You allergic benzodiazepine ( tranquilizer ) . You liver disorder . You receive nonnucleoside reverse transcriptase inhibitor ( class antiHIV drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Labor</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>